Associated Papers
A prospective, multicenter, comprehensive genomic profile signature study in patients with EGFR-mutant advanced non-small cell lung cancer at the first-line treatment failure of osimertinib.
Shi Y et al.
Signal Transduction and Targeted Therapy, 2025
41326340 (PubMed )
Supplement: 41392_2025_2481_MOESM1_ESM.docx
Histological evidence of MAPK pathway activation across subtypes of adult orbital xanthogranulomatous disease irrespective of the detection of oncogenic mutations.
Detiger SE et al.
Clinical Immunology (orlando, Fla.), 2024
KRAS G12C mutations in Asia: a landscape analysis of 11,951 Chinese tumor samples.
Loong HH et al.
Translational Lung Cancer Research, 2020
A Real-World Study in Advanced Non-Small Cell Lung Cancer with KRAS Mutations.
Lei L et al.
Translational Oncology, 2020
Analysis of KRAS and BRAF genes mutation in the central nervous system metastases of non-small cell lung cancer.
Nicoś M et al.
Clinical and Experimental Medicine, 2016
C4ST-1/CHST11-controlled chondroitin sulfation interferes with oncogenic HRAS signaling in Costello syndrome.
Klüppel M et al.
European Journal of Human Genetics : Ejhg, 2012
The RASopathies: developmental syndromes of Ras/MAPK pathway dysregulation.
Tidyman WE et al.
Current Opinion in Genetics & Development, 2009
The RAS/MAPK syndromes: novel roles of the RAS pathway in human genetic disorders.
Aoki Y et al.
Human Mutation, 2008
Mutation and phenotypic spectrum in patients with cardio-facio-cutaneous and Costello syndrome.
Schulz AL et al.
Clinical Genetics, 2008
Further evidence of genetic heterogeneity in Costello syndrome: involvement of the KRAS gene.
Bertola DR et al.
Journal of Human Genetics, 2007
Select a paper to view details